232 related articles for article (PubMed ID: 11961396)
1. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
Akizawa T; Koshikawa S; Iida N; Marumo F; Akiba T; Kawaguchi Y; Imada A; Yamazaki C; Suzuki M; Tubakihara Y
Nephron; 2002 Apr; 90(4):384-90. PubMed ID: 11961396
[TBL] [Abstract][Full Text] [Related]
2. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
Iida N; Koshikawa S; Akizawa T; Tsubakihara Y; Marumo F; Akiba T; Kawaguchi Y; Imada A; Yamazaki C; Suzuki M
Am J Nephrol; 2002; 22(4):338-46. PubMed ID: 12169865
[TBL] [Abstract][Full Text] [Related]
3. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
[TBL] [Abstract][Full Text] [Related]
4. Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension.
Fujisaki K; Kanai H; Hirakata H; Nakamura S; Koga Y; Hattori F; Iida M
Ther Apher Dial; 2007 Feb; 11(1):49-55. PubMed ID: 17309575
[TBL] [Abstract][Full Text] [Related]
5. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
Freeman R; Landsberg L; Young J
Neurology; 1999 Dec; 53(9):2151-7. PubMed ID: 10599797
[TBL] [Abstract][Full Text] [Related]
6. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
Kaufmann H; Saadia D; Voustianiouk A; Goldstein DS; Holmes C; Yahr MD; Nardin R; Freeman R
Circulation; 2003 Aug; 108(6):724-8. PubMed ID: 12885750
[TBL] [Abstract][Full Text] [Related]
7. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance.
Tanaka H; Yamaguchi H; Mino M
Clin Auton Res; 1996 Aug; 6(4):189-93. PubMed ID: 8902314
[TBL] [Abstract][Full Text] [Related]
8. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
Hoeldtke RD; Cilmi KM; Mattis-Graves K
Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
[TBL] [Abstract][Full Text] [Related]
9. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
Lamotte G; Holmes C; Sullivan P; Goldstein DS
Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336
[TBL] [Abstract][Full Text] [Related]
10. Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.
Carvalho MJ; van den Meiracker AH; Boomsma F; Man in 't Veld AJ; Freitas J; Costa O; de Freitas AF
J Auton Nerv Syst; 1997 Jan; 62(1-2):63-71. PubMed ID: 9021651
[TBL] [Abstract][Full Text] [Related]
11. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
Birkmayer W; Birkmayer G; Lechner H; Riederer P
J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
[TBL] [Abstract][Full Text] [Related]
12. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
Sakoda S; Suzuki T; Higa S; Ueji M; Kishimoto S; Matsumoto M; Yoneda S
Eur Neurol; 1985; 24(5):330-4. PubMed ID: 3932074
[TBL] [Abstract][Full Text] [Related]
13. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Julien C; Lenders J; Schalekamp MA
J Hypertens Suppl; 1988 Dec; 6(4):S547-9. PubMed ID: 3149290
[TBL] [Abstract][Full Text] [Related]
14. [Effects of L-threo-Dops on orthostatic hypotension in Parkinson's disease].
Yanagisawa N; Ikeda S; Hashimoto T; Hanyu N; Nakagawa S; Fujimori N; Ushiyama M
No To Shinkei; 1998 Feb; 50(2):157-63. PubMed ID: 9513205
[TBL] [Abstract][Full Text] [Related]
15. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
Pérez-Lloret S; Quarracino C; Otero-Losada M; Rascol O
Expert Opin Pharmacother; 2019 Apr; 20(6):635-645. PubMed ID: 30730771
[TBL] [Abstract][Full Text] [Related]
16. Treatment of dialysis-induced hypotension with L-threo-3,4-dihydroxyphenylserine.
Iida N; Tsubakihara Y; Shirai D; Imada A; Suzuki M
Nephrol Dial Transplant; 1994; 9(8):1130-5. PubMed ID: 7800213
[TBL] [Abstract][Full Text] [Related]
17. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
Hauser RA; Hewitt LA; Isaacson S
J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693
[TBL] [Abstract][Full Text] [Related]
18. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G
Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613
[TBL] [Abstract][Full Text] [Related]
19. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Kaufmann H; Freeman R; Biaggioni I; Low P; Pedder S; Hewitt LA; Mauney J; Feirtag M; Mathias CJ;
Neurology; 2014 Jul; 83(4):328-35. PubMed ID: 24944260
[TBL] [Abstract][Full Text] [Related]
20. [A case of diabetic orthostatic hypotension effectively managed with L-dops (L-threo-3,4-dihydroxyphenylserine)].
Yoshikawa H; Kawai K; Inoue S; Murayama Y; Kuzuya N; Fujita T; Koide Y; Yamashita K; Yoshizawa K; Mizusawa H
Nihon Naika Gakkai Zasshi; 1987 Nov; 76(11):1695-700. PubMed ID: 3151075
[No Abstract] [Full Text] [Related]
[Next] [New Search]
